Back to News
Market Impact: 0.2
Nxera Secures $10 Mln Milestone Pay As FDA Accepts Neurocrine's IND Of NBI-1117567 In Alzheimer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Nxera Pharma said its partner Neurocrine Biosciences received FDA acceptance of its IND for a Phase 2 study of NBI-1117567. While the update is early (IND acceptance rather than trial results), it is a meaningful regulatory milestone that de-risks the program’s path to Phase 2 study initiation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
NBIX0.35
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search
- Automating Financial Model Updates: A Source-Controlled Workflow